• Iovance Biotherapeutics (NASDAQ:IOVA) is down 12% in after-hours trading Thursday despite posting Q3 results that beat on both lines and reaffirming its fiscal 2024 revenue guidance.
• The biotech still sees full-year product sales of $160M-$165M. Revenue consensus is $162.71M. The company also reiterated its

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。